ValuEngine upgraded shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) from a strong sell rating to a sell rating in a report released on Friday morning.
A number of other research analysts have also commented on BLPH. Zacks Investment Research lowered Bellerophon Therapeutics from a buy rating to a hold rating in a report on Wednesday, September 6th. HC Wainwright reissued a buy rating and set a $5.00 price target on shares of Bellerophon Therapeutics in a report on Wednesday, September 6th.
Bellerophon Therapeutics (BLPH) opened at 1.16 on Friday. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.98. The firm’s market capitalization is $41.19 million. The stock has a 50 day moving average of $1.20 and a 200-day moving average of $1.36.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. On average, equities analysts predict that Bellerophon Therapeutics will post ($1.12) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://sportsperspectives.com/2017/09/11/bellerophon-therapeutics-inc-blph-upgraded-at-valuengine.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in BLPH. Susquehanna International Group LLP acquired a new stake in Bellerophon Therapeutics during the 2nd quarter worth about $1,316,000. Renaissance Technologies LLC lifted its holdings in shares of Bellerophon Therapeutics by 99.7% during the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 238,300 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 211,111 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Bellerophon Therapeutics during the 1st quarter valued at about $125,000. Hedge funds and other institutional investors own 45.85% of the company’s stock.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.